Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KYMR
#885
Kymera Therapeutics, Inc. Common Stock
91.350
0
+1.44%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+1.44%
Mudança mensal
+25.93%
Mudança em 6 meses
+54.57%
Mudança anual
+54.57%
Fechamento anterior
90.050
0
Open
91.380
0
Bid
Ask
Low
91.350
0
High
91.380
0
Volume
150
Mercados
Ações
Cuidados de saúde
KYMR
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
64.77 M
64.94 M
65.12 M
71.5 M
71.95 M
81.64 M
—
Valuation ratios
Enterprise value
2.95 B
2.49 B
1.69 B
2.78 B
3.96 B
6 B
14.43 B
Price to earnings ratio
-20.23
-13.5
-8.8
-12.54
-15.72
-21.09
-58.15
Price to sales ratio
34.46
64.14
35
76.8
102.79
—
—
Price to cash flow ratio
-27.79
-15.52
-8.85
-13.46
-19.62
28.23
-13.71
Price to book ratio
1.23
3.61
0.64
0.97
1.27
4.16
7.04
Enterprise value to EBITDA ratio
—
-8.27
—
—
-10.77
—
—
Profitability ratios
Return on assets %
0.06
0.07
0.07
0.07
0.07
0.05
0.26
Return on equity %
0.07
0.08
0.08
0.08
0.09
0.06
0.3
Return on invested capital %
—
—
—
—
—
28.31
—
Gross margin %
100
0
0
0
0
0
0
Operating margin %
1 927.93
1 092.17
336.77
736.82
3 347.36
3 409.79
7 830.73
EBITDA margin %
—
-1 165.3
-427.5
-818.66
-3 369.61
-3 439.01
-8 054.78
Net margin %
1 670.33
956.88
296.75
667.6
2 973.05
3 029.64
6 967.04
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.55
7.53
8.49
8.32
7.38
10.47
34.66
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.01
0.02
0.01
0
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.66
0.82
0.99
0.74
0.31
0.79
2.83
EBIT per share
—
-1.17
-1.2
-1.19
-1.09
-1.19
-4.68
EBITDA per share
—
-1.15
-1.18
-1.17
-1.07
-1.17
-4.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
7.22
6.51
5.78
8.27
5.79
10.04
29.88
Net current asset value per share
7.47
6.8
6.25
9.05
6.05
10.31
31.67
Tangible book value per share
11.73
11.14
9.81
12.08
10.84
18.7
51.42
Working capital per share
6.6
5.9
5.51
7.97
5.23
9.33
28.04
Book value per share
11.73
11.14
9.81
12.08
10.84
18.7
51.42
Notícias
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Morgan Stanley снизил целевую цену акций Kymera Therapeutics
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress
RBC Capital повышает целевую цену Kymera Therapeutics
RBC Capital raises Kymera Therapeutics price target on pipeline progress
RBC Capital raises Kymera Therapeutics price target on pipeline
Stifel подтверждает рейтинг Buy для Kymera Therapeutics по $114
Stifel reiterates Buy rating on Kymera Therapeutics stock at $114
Kymera Q4 2025 slides: pipeline advances despite revenue miss
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics запускает размещение акций на $500 млн
Kymera Therapeutics launches $500 million at-the-market stock offering